Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roberto Stasi

Blood

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Blood|November 15, 2012
How I treat thrombocytopenia in pregnancyTerry Gernsheimer, Andra H James, Roberto Stasi
Blood|February 28, 2002
Sustained response to recombinant human erythropoietin and intermittent all-trans retinoic acid in patients with myelodysplastic syndromesRoberto Stasi, Maurizio Brunetti, Edmondo Terzoli, et al.
Blood|March 5, 2004
Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophiliaRoberto Stasi, Maurizio Brunetti, Elisa Stipa, et al.
Blood|April 1, 2008
Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximabRoberto Stasi, Nichola Cooper, Giovanni Del Poeta, et al.
Blood|June 6, 2007
Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpuraRoberto Stasi, Giovanni Del Poeta, Elisa Stipa, et al.
Blood|November 8, 2007
Impact of immune thrombocytopenia on the clinical course of chronic lymphocytic leukemiaCarlo Visco, Marco Ruggeri, Maria Laura Evangelista, et al.
Blood|October 24, 2008
Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic reviewRoberto Stasi, Ameet Sarpatwari, Jodi B Segal, et al.
Blood|March 12, 2005
Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 studySergio Amadori, Stefan Suciu, Ulrich Jehn, et al.
Blood|May 9, 2012
Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopeniaVivek L Patel, Matthieu Mahévas, Soo Y Lee, et al.
Blood|January 31, 2013
Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working GroupFrancesco Rodeghiero, Marc Michel, Terry Gernsheimer, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Blood|November 15, 2012
How I treat thrombocytopenia in pregnancyTerry Gernsheimer, Andra H James, Roberto Stasi
Blood|February 28, 2002
Sustained response to recombinant human erythropoietin and intermittent all-trans retinoic acid in patients with myelodysplastic syndromesRoberto Stasi, Maurizio Brunetti, Edmondo Terzoli, et al.
Blood|March 5, 2004
Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophiliaRoberto Stasi, Maurizio Brunetti, Elisa Stipa, et al.
Blood|April 1, 2008
Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximabRoberto Stasi, Nichola Cooper, Giovanni Del Poeta, et al.
Blood|June 6, 2007
Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpuraRoberto Stasi, Giovanni Del Poeta, Elisa Stipa, et al.
Blood|November 8, 2007
Impact of immune thrombocytopenia on the clinical course of chronic lymphocytic leukemiaCarlo Visco, Marco Ruggeri, Maria Laura Evangelista, et al.
Blood|October 24, 2008
Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic reviewRoberto Stasi, Ameet Sarpatwari, Jodi B Segal, et al.
Blood|March 12, 2005
Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 studySergio Amadori, Stefan Suciu, Ulrich Jehn, et al.
Blood|May 9, 2012
Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopeniaVivek L Patel, Matthieu Mahévas, Soo Y Lee, et al.
Blood|January 31, 2013
Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working GroupFrancesco Rodeghiero, Marc Michel, Terry Gernsheimer, et al.
Pageof 2